Bronchoalveolar lavage fluid and serum complement activity in pulmonary sarcoidosis. 1986

C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon

In this work, using bronchoalveolar lavage fluids (BALF), we demonstrated the presence of complement within airways by assaying hemolytic activity of the whole classical pathway (CH50) and by measuring the complement component C2 (C2H50). Patients with sarcoidosis, patients with idiopathic pulmonary fibrosis (IPF), and healthy control subjects were compared. No CH50 activity was found in BALF from healthy control subjects (n = 9), but some activity (mean, 20 CH50) was associated with IPF (n = 7). Complement activities ranged from 40 to 554 CH50 in patients with sarcoidosis (n = 27). During the treatment, complement activity decreased in BALF from the few patients in our series who received corticotherapy. C2 hemolytic activity was detected in BALF from the normal control group (in the absence of CH50 activity). In the sarcoidosis and IPF groups when CH50 was present, the variations in the C2/CH50 ratio were studied. The high ratio observed in BALF from patients with sarcoidosis and a chronic derangement of alveolar structure suggests either an increased C2 production or an alternative complement pathway (C2-independent) activation within their lungs.

UI MeSH Term Description Entries
D007122 Immunoelectrophoresis A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
D007507 Therapeutic Irrigation The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis. Douching,Lavage,Douchings,Irrigation, Therapeutic,Irrigations, Therapeutic,Lavages,Therapeutic Irrigations
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011650 Pulmonary Alveoli Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place. Alveoli, Pulmonary,Alveolus, Pulmonary,Pulmonary Alveolus
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003175 Complement C2 A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE). C2 Complement,Complement 2,Complement Component 2,C2, Complement,Complement, C2,Component 2, Complement
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3

Related Publications

C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
April 2015, Scandinavian journal of immunology,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
January 2005, Medicinski pregled,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
January 1986, Annals of the New York Academy of Sciences,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
October 1981, Thorax,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
January 1990, Japanese journal of medicine,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
May 1999, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
January 1995, Acta cytologica,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
January 1989, Nihon Kyobu Shikkan Gakkai zasshi,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
May 2006, American journal of respiratory and critical care medicine,
C R Lambré, and S le Maho, and G di Bella, and H de Cremoux, and K Atassi, and J Bignon
October 2005, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG,
Copied contents to your clipboard!